15 completed, 3 unknown, 1 not yet recruiting. 14 Phase 1, 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 13, Unknown 1 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow GL Pharm Tech Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. W2505, W2505-P1, W2505-R - Erectile Dysfunctions | Phase 3 | Not yet recruiting | GL Pharm Tech Corporation | 228 | 2026-09-01 | 2026-10-05 |
| Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients AJU-S56 5%, Placebo Group(Vehicle) - Dry Eye Syndromes | Phase 3 | Unknown | AJU Pharm Co., Ltd. | 396 | 2023-11-10 | 2024-04-08 |
| Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients (AJU-S56 5% and placebo), AJU-S56 5%, Placebo(Vehicle) - Dry Eye Syndromes | Phase 2 | Completed | AJU Pharm Co., Ltd. | 99 | 2021-11-22 | 2024-04-29 |
| Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease 5% GLH8NDE, Placebo - Dry Eye Syndromes | Phase 2 | Unknown | GL Pharm Tech Corporation | 99 | 2021-04-01 | 2021-01-06 |
| A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers 5% GLH8NDE, Placebos - Dry Eye Syndromes | Phase 1 | Completed | GL Pharm Tech Corporation | 39 | 2019-09-26 | 2020-12-19 |
| The Pharmacokinetics of GLA5PR Tablet According to the Renal Function GLA5PR tablet 75 mg, GLA5PR tablet 150 mg - Neuropathic Pain | Phase 1 | Unknown | GL Pharm Tech Corporation | 24 | 2019-09-17 | 2020-07-23 |
| Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed) Janumet XR tablet 100/1000 mg, GLH1SM tablet 100/1000 mg - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 25 | 2019-05-02 | 2020-07-23 |
| Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers Janumet XR tablet 100/1000 mg, GLH1SM tablet 100/1000 mg - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 30 | 2019-01-02 | 2019-04-24 |
| Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg GLA5PR GLARS-NF3 tablet 300mg, GLA5PR GLARS-NF1 tablet 300mg - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 24 | 2016-11-01 | 2017-04-12 |
| Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg GLA5PR GLARS-NF3 tablet 150mg, GLA5PR GLARS-NF1 tablet 150mg - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 24 | 2016-11-01 | 2017-04-12 |
| A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers Pregabalin 150mg, Pregabalin 300mg - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 40 | 2014-10-01 | 2014-12-30 |
| Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS Tamsulosin HCL 0.4mg, Tamsulosin HCL 0.2mg - Benign Prostatic Hyperplasia | Phase 3 | Completed | GL Pharm Tech Corporation | 309 | 2014-03-01 | 2016-02-25 |
| PK Study of Pregabalin GLARS Tablet 150mg and IR Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects Pregabalin 150mg, Pregabalin 75mg - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 24 | 2014-02-01 | 2014-11-13 |
| A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects Pregabalin 150mg, Pregabalin 75mg - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 30 | 2013-10-01 | 2014-12-30 |
| A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers GL2702 GLARS-NF1, Omix Ocas - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 36 | 2013-08-01 | 2019-01-10 |
| A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers GL2907, Oxycontine CR 10mg - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 24 | 2013-04-01 | 2014-11-13 |
| A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects Pregabalin - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 30 | 2012-10-01 | 2013-01-28 |
| A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers Oxycodone - Healthy | Phase 1 | Completed | GL Pharm Tech Corporation | 24 | 2012-03-01 | 2013-01-28 |
| PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination In combination of 0.2mg finasteride and 5mg tamsulosin, GL2701 capsule - Benign Prostatic Hyperplasia (BPH) | Phase 1 | Completed | Korea University Anam Hospital | 26 | 2012-01-01 | 2013-04-11 |
Dry Eye Syndromes (4) · Neuralgia (3) · Diabetic Neuropathies (2) · Neuralgia, Postherpetic (2) · Prostatic Hyperplasia (2) · Erectile Dysfunction (1)
Pregabalin (4) · Tamsulosin (3) · Drug Evaluation (2) · Metformin (2) · Oxycodone (2) · Sitagliptin Phosphate (2) · Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination (2) · Control Groups (1) · Finasteride (1)
South Korea (17)
Doo-Yeoun Cho, MD (2) · Kyungho Jang, MD, Ph.D (2) · Min-Gul Kim, Ph.D. (2) · Dong-seok Yim (1) · Ji-Young Park, MD, PhD (1) · Min-Gul Kim, MD (1) · Min-Gul Kim, MD, Ph.D. (1) · MinChang Kwon, Ph. D (1) · Minchang Kwon, Ph. D (1) · You T Gun, MD (1)